INTRODUCTION: Seizure liability is an adverse property of new candidate drugs typically
detected only in later stage pre-clinical safety studies. Consequently, pharmaceutical
discovery needs small scale (microplate-based), rapid throughput screens to 'front-load'such
adverse endpoints in order to reduce associated attrition rates. Of the potential methods
available, previously published studies have shown that the quantification of seizure-
associated locomotion in the larval zebrafish (Danio rerio) offers high potential for …